Mylan doxepin label update approved; Viatris-linked contact lens comfort trial begins recruiting
A labeling supplement for Mylan's generic doxepin hydrochloride was approved, and a new trial testing Viatris's Tyrvaya in contact lens wearers started recruiting.
Two items surfaced this week involving Viatris and its Mylan Pharms Inc unit.
- A labeling supplement (submission number 40) for Mylan's doxepin hydrochloride capsules, covering strengths from 10mg to 100mg base, was approved as of the July 16, 2026 status date.1
- A new study titled "A Clinical Evaluation of Treating Contact Lens Discomfort With Varenicline Solution Nasal Spray 0.03mg" is recruiting, led by Ocular Aesthetics, LLC dba Ocular Clinical Trials with Viatris Inc. as a collaborator.2 The trial will test whether Tyrvaya, a twice-daily nasal spray approved for dry eye disease, improves contact lens comfort, with an estimated enrollment of 50 participants.2
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.